Schizophrenia, tardive dyskinesia, and brain GABA.
We measured the contents of gamma-aminobutyric acid (GABA) and of other amino compounds in five regions of autopsied brain from 18 patients with schizophrenia and from a large group of adult control subjects dying without any neurological or psychiatric disorder. In addition, concentrations of GABA were measured in the cerebrospinal fluid (CSF) of living schizophrenic patients and control subjects. No deficiency of GABA was found in the frontal cortex, caudate nucleus, putamen, nucleus accumbens, or medial dorsal thalamus of patients dying with schizophrenia, nor were GABA concentrations low in the CSF of living schizophrenic patients. These results do not confirm our earlier report of low levels of GABA in the nucleus accumbens and thalamus of some schizophrenic patients. We do not find neurochemical evidence favoring an involvement of GABAergic neuronal hypofunction in the etiology either of schizophrenia or of neuroleptic-induced tardive dyskinesia.
Perry
T L
TL
Department of Pharmacology & Therapeutics, University of British Columbia, Vancouver, Canada.
Hansen
S
S
Jones
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D004409:Dyskinesia, Drug-Induced / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011963:Receptors, GABA-A / Q000187:drug effects; D012559:Schizophrenia / Q000134:cerebrospinal fluid*; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D014150:Antipsychotic Agents; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid